The pattern recognition reagents RAGE VC1 and peptide p5 share common binding sites and exhibit specific reactivity with AA amyloid in mice

References

• Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005;83:876–86
   PubMed Web of Science ®Google Scholar
• Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT, Taguchi A, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117–28
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000;1498:99–111
   PubMed Web of Science ®Google Scholar
• Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002;54:1615–25
   PubMed Web of Science ®Google Scholar
• Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009;7:17. doi: 10.1186/1479-5876-7-17
   PubMed Web of Science ®Google Scholar
• Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med 2009;4:389–401
   PubMed Web of Science ®Google Scholar
• Yan SF, Ramasamy R, Schmidt AM. Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol 2010;79:1379–86
   PubMed Web of Science ®Google Scholar
• Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, Fritz G. Structural basis for ligand recognition and activation of RAGE. Structure 2010;18:1342–52
   PubMed Web of Science ®Google Scholar
• Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002;1:1–15
   PubMed Web of Science ®Google Scholar
• Arancio O, Zhang HP, Chen X, Lin C, Trinchese F, Puzzo D, Liu S, et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004;23:4096–105
   PubMed Web of Science ®Google Scholar
• Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, Walker DG, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J 2010;24:1043–55
   PubMed Web of Science ®Google Scholar
• Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX. RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease. Front Biosci (Schol Ed) 2012;4:240–50
   PubMedGoogle Scholar
• Blancas-Mejia LM, Ramirez-Alvarado M. Systemic amyloidoses. Annu Rev Biochem 2013;82:745–74
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–96
   PubMed Web of Science ®Google Scholar
• Pepys MB. Amyloidosis. Annu Rev Med 2006;57:223–41
   PubMed Web of Science ®Google Scholar
• Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6:643–51
   PubMed Web of Science ®Google Scholar
• Rocken C, Kientsch-Engel R, Mansfeld S, Stix B, Stubenrauch K, Weigle B, Buhling F, et al. Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis. Am J Pathol 2003;162:1213–20
   PubMed Web of Science ®Google Scholar
• Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907–13
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:206–12
   PubMed Web of Science ®Google Scholar
• Saito S, Ihara M. New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci 2014;6:290. doi: 10.3389/fnagi.2014.00290
   PubMed Web of Science ®Google Scholar
• Walker D, Lue LF, Paul G, Patel A, Sabbagh MN. Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs 2015;24:393–9
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim H, Kim YH, Roh EJ, Han H, Shin KJ. Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer's disease. Bioorg Med Chem Lett 2012;22:7555–61
   PubMed Web of Science ®Google Scholar
• Yan SD, Bierhaus A, Nawroth PP, Stern DM. RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis 2009;16:833–43
   PubMed Web of Science ®Google Scholar
• Haupt C, Bereza M, Kumar ST, Kieninger B, Morgado I, Hortschansky P, Fritz G, et al. Pattern recognition with a fibril-specific antibody fragment reveals the surface variability of natural amyloid fibrils. J Mol Biol 2011;408:529–40
   PubMed Web of Science ®Google Scholar
• Haupt C, Morgado I, Kumar ST, Parthier C, Bereza M, Hortschansky P, Stubbs MT, et al. Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. J Mol Biol 2011;405:341–8
   PubMed Web of Science ®Google Scholar
• Smits NC, Kurup S, Rops AL, ten Dam GB, Massuger LF, Hafmans T, Turnbull JE, et al. The heparan sulfate motif (GlcNS6S-IdoA2S)3, common in heparin, has a strict topography and is involved in cell behavior and disease. J Biol Chem 2010;285:41143–51
   PubMed Web of Science ®Google Scholar
• Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 2012;7:e52686
   PubMed Web of Science ®Google Scholar
• Wall JS, Richey T, Stuckey A, Donnell R, Macy S, Martin EB, Williams A, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci USA 2011;108:E586–94
   Web of Science ®Google Scholar
• Wall JS, Richey T, Stuckey A, Donnell R, Oosterhof A, van Kuppevelt TH, Smits NC, et al. SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies. Nucl Med Biol 2012;39:65–75
   PubMed Web of Science ®Google Scholar
• Wall JS, Williams A, Richey T, Stuckey A, Huang Y, Wooliver C, Macy S, et al. A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo. PLoS One 2013;8:e66181
   PubMed Web of Science ®Google Scholar
• Martin EB, Kennel SJ, Richey T, Wooliver C, Osborne D, Williams A, Stuckey A, et al. Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation. Peptides 2014;60:63–70
   PubMed Web of Science ®Google Scholar
• Wall JS, Richey T, Williams A, Stuckey A, Osborne D, Martin E, Kennel SJ. Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Mol Imaging Biol 2012;14:402–7
   PubMed Web of Science ®Google Scholar
• Wall JS, Martin EB, Richey T, Stuckey AC, Macy S, Wooliver C, Williams A, et al. Preclinical validation of the heparin-reactive peptide p5+14 as a molecular imaging agent for visceral amyloidosis. Molecules 2015;20:7657–82
   PubMed Web of Science ®Google Scholar
• Dattilo BM, Fritz G, Leclerc E, Kooi CW, Heizmann CW, Chazin WJ. The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 2007;46:6957–70
   PubMed Web of Science ®Google Scholar
• Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, Solomon A. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry 1999;38:14101–8
   PubMed Web of Science ®Google Scholar
• Wall JS, Paulus MJ, GLeason S, Gregor J, Solomon A, Kennel SJ. Micro-imaging of amyloid in mice. Meth Enzymol 2006;412:161–82
   PubMed Web of Science ®Google Scholar
• Tran T, Engfeldt T, Orlova A, Widstrom C, Bruskin A, Tolmachev V, Karlstrom AE. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem 2007;18:549–58
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss DT, Schell M, Hrncic R, Murphy CL, Wall J, McGavin MD, et al. Transgenic mouse model of AA amyloidosis. Am J Pathol 1999;154:1267–72
   PubMed Web of Science ®Google Scholar
• Wall JS, Richey T, Allen A, Donnell R, Kennel SJ, Solomon A. Quantitative tomography of early-onset spontaneous AA amyloidosis in interleukin 6 transgenic mice. Comp Med 2008;58:542–50
   PubMed Web of Science ®Google Scholar
• Iconomidou VA, Hamodrakas SJ. Natural protective amyloids. Curr Protein Pept Sci 2008;9:291–309
   PubMed Web of Science ®Google Scholar
• Lindahl B, Lindahl U. Amyloid-specific heparan sulfate from human liver and spleen. J Biol Chem 1997;272:26091–4
   PubMed Web of Science ®Google Scholar
• Stenstad T, Magnus JH, Husby G. Characterization of proteoglycans associated with mouse splenic AA amyloidosis. Biochem J 1994;303:663–70
   PubMed Web of Science ®Google Scholar
• Sugumaran G, Elliott-Bryant R, Phung N, Vitseva O, Kuberan B, Lech M. Characterization of splenic glycosaminoglycans accumulated in vivo in experimentally induced amyloid-susceptible and amyloid-resistant mice. Scand J Immunol 2004;60:574–83
   PubMed Web of Science ®Google Scholar
• Wall JS, Solomon A, Kennel SJ. Development and evaluation of agents for targeting visceral amyloid. Tijdschr Nucl Geneeskd 2011;33:807–14
   PubMedGoogle Scholar
• Rullo A, Nitz M. Importance of the spatial display of charged residues in heparin-peptide interactions. Biopolymers 2009;93:290–8
   Web of Science ®Google Scholar
• Nagai R, Matsumoto K, Ling X, Suzuki H, Araki T, Horiuchi S. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes 2000;49:1714–23
   PubMed Web of Science ®Google Scholar
• Xu D, Young JH, Krahn JM, Song D, Corbett KD, Chazin WJ, Pedersen LC, et al. Stable RAGE-heparan sulfate complexes are essential for signal transduction. ACS Chem Biol 2013;8:1611–20
   PubMed Web of Science ®Google Scholar
• Liu R, Mori S, Wake H, Zhang J, Liu K, Izushi Y, Takahashi HK, et al. Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding. Acta Med Okayama 2009;63:203–11
   PubMed Web of Science ®Google Scholar
• Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target? Curr Opin Investig Drugs 2006;7:985–91
   PubMed Web of Science ®Google Scholar